Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions

被引:100
作者
Handkiewicz-Junak, Dada [2 ]
Czarniecka, Agnieszka [3 ,4 ]
Jarzab, Barbara [1 ,2 ]
机构
[1] Maria Sklodowska Curie Mem Canc Ctr, Dept Nucl Med & Endocrine Oncol, PL-44100 Gliwice, Poland
[2] Gliwice Branch, Inst Oncol, PL-44100 Gliwice, Poland
[3] Maria Sklodowska Curie Mem Canc Ctr, Dept Surg Oncol, PL-44100 Gliwice, Poland
[4] Gliwice Branch, Inst Oncol, PL-44100 Gliwice, Poland
关键词
Papillary thyroid cancer; Follicular thyroid cancer; Prognosis; BRAF; Molecular markers; LYMPH-NODE METASTASIS; ENDOTHELIAL GROWTH-FACTOR; BRAF V600E MUTATION; GENE-EXPRESSION PROFILES; AGGRESSIVE TUMOR PHENOTYPES; IODIDE-METABOLIZING GENES; DIFFERENT STAGING SYSTEMS; ENDEMIC GOITER REGION; HIGH PREVALENCE; RET/PTC REARRANGEMENTS;
D O I
10.1016/j.mce.2010.01.007
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Gene expression profiling shows that, by gene signature, the difference between BRAF-positive and BRAF-negative PTC is so distinct that BRAF-positive cancer may be regarded as a molecular subtype of papillary thyroid cancer (PTC). Since much enthusiasm surrounds the BRAF-oncogene as a molecular prognostic factor, a central focus of our consideration is to weigh the current arguments for and against applying BRAF mutation status of the tumor in clinical practice. The frequency of BRAF mutation in PTC is high-45% on average, with values over 70-80% in some populations. This will mean that implementing BRAF mutation as a factor of poor prognosis will shift many PTC patients, considered up to now as low risk ones, to the more extensive treatment. We estimate that 31% of all PTC patients and 39% of those diagnosed with stage I-II disease will face the risk of overtreatment if the decision will be based on the BRAF-positivity of their tumors. Also, the risk of undertreatment in the young patients with BRAF-negative tumors is evaluated with 26%. We think that, as of now, the evidence-based support for such consequences is still weak. Thus, there is urgent need to look for genes or gene signatures which will be helpful in the stratification of BRAF-positive tumors to specify these with poor prognosis with higher accuracy, needed for clinical decisions. Considering this, in the review we summarize the present status of knowledge on other prognosis-related gene expression changes in papillary and follicular cancer and relate them to he tumor's biology. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:8 / 28
页数:21
相关论文
共 265 条
[31]   Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer [J].
Cooper, David S. ;
Doherty, Gerard M. ;
Haugen, Bryan R. ;
Kloos, Richard T. ;
Lee, Stephanie L. ;
Mandel, Susan J. ;
Mazzaferri, Ernest L. ;
McIver, Bryan ;
Pacini, Furio ;
Schlumberger, Martin ;
Sherman, Steven I. ;
Steward, David L. ;
Tuttle, R. Michael .
THYROID, 2009, 19 (11) :1167-1214
[32]   BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma [J].
Costa, Angela M. ;
Herrero, Agustin ;
Fresno, Manuel F. ;
Heymann, Jonas ;
Antonio Alvarez, Jose ;
Cameselle-Teijeiro, Jose ;
Garcia-Rostan, Ginesa .
CLINICAL ENDOCRINOLOGY, 2008, 68 (04) :618-634
[33]  
CZARNIECKA A, 2004, INDICATION LESS TOTA
[34]   Prognostic scoring systems in patients with follicular thyroid cancer: A comparison of different staging systems in predicting the patient outcome [J].
D'Avanzo, A ;
Ituarte, P ;
Treseler, P ;
Kebebew, E ;
Wu, J ;
Wong, M ;
Duh, QY ;
Siperstein, AE ;
Clark, OH .
THYROID, 2004, 14 (06) :453-458
[35]   A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors [J].
Dankort, David ;
Filenova, Elena ;
Collado, Manuel ;
Serrano, Manuel ;
Jones, Kirk ;
McMahon, Martin .
GENES & DEVELOPMENT, 2007, 21 (04) :379-384
[36]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[37]   NATURAL-HISTORY, TREATMENT, AND COURSE OF PAPILLARY THYROID-CARCINOMA [J].
DEGROOT, LJ ;
KAPLAN, EL ;
MCCORMICK, M ;
STRAUS, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) :414-424
[38]  
DeLuca Amena M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000604
[39]  
DIRENZO MF, 1992, ONCOGENE, V7, P2549
[40]   Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy [J].
Durante, C. ;
Haddy, N. ;
Baudin, E. ;
Leboulleux, S. ;
Hartl, D. ;
Travagli, J. P. ;
Caillou, B. ;
Ricard, M. ;
Lumbroso, J. D. ;
De Vathaire, F. ;
Schlumberger, M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (08) :2892-2899